Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis
نویسندگان
چکیده
منابع مشابه
Update on immune checkpoint inhibitors in lung cancer.
BACKGROUND The immune checkpoint proteins, including the B7/CD28 receptor superfamily, have become increasingly important targets for pharmacologic blockade. Several classes of new agents have impressive clinical activity, and their eventual approval for treatment of lung cancer seems likely. METHODS This article discusses the current development of these agents, including the CTLA-4, PD-1, a...
متن کاملImmune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
1Phase I Early Clinical Trials Unit, Department of Oncology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium 2Consorci Hospital General Universitari de Valencia, Valencia, Comunitat Valenciana, Spain 3Early Development Drugs Unit, Medical Oncology Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile 4Department of Oncology, Universita degli Studi di Palermo, Palermo...
متن کاملImmune checkpoint inhibitors in cancer therapy.
In recent years immune checkpoint inhibitors have garnered attention as being one of the most promising types of immunotherapy on the horizon. There has been particular focus on the immune checkpoint molecules, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) which have been shown to have potent immunomodulatory effects through their function as negative regu...
متن کاملCancer immunotherapy beyond immune checkpoint inhibitors
Malignant cells have the capacity to rapidly grow exponentially and spread in part by suppressing, evading, and exploiting the host immune system. Immunotherapy is a form of oncologic treatment directed towards enhancing the host immune system against cancer. In recent years, manipulation of immune checkpoints or pathways has emerged as an important and effective form of immunotherapy. Agents t...
متن کاملCancer vaccine: learning lessons from immune checkpoint inhibitors
Cancer vaccines have been exclusively studied all through the past decades, and have made exceptional achievements in cancer treatment. Few cancer vaccines have been approved by the US Food and Drug Administration (FDA), for instance, Provenge, which was approved for the treatment of prostate carcinoma in 2012. Moreover, more recently, T-VEC got approval for the treatment of melanoma. While, th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2016
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.07.028